Multivariate logistic regression analysis of the association between marrow fibrosis and JAK2- or MPL-mutant allele burden in patients with ET or post-ET myelofibrosis belonging to the Pavia cohort (see Table 1)
| Risk factors for the presence of fibrosis (covariates) . | Odds ratio . | P . | 95% CI . |
|---|---|---|---|
| Model 1 (including JAK2-mutated, MPL-mutated, and JAK2/MPL-unmutated patients) | |||
| Age at diagnosis (y) | 1.01 | .225 | 0.99-1.03 |
| MPL exon 10 mutation vs JAK2 (V617F) | 3.22 | .017 | 1.24-8.40 |
| MPL exon 10 mutation vs JAK2/MPL-unmutated patients | 1.64 | .323 | 0.62-4.37 |
| Model 2 (including JAK2-mutated and MPL-mutated patients exclusively) | |||
| Age at diagnosis (y) | 1.01 | .396 | 0.99-1.04 |
| MPL exon 10 mutation vs JAK2 (V617F) | 2.42 | .116 | 0.80-7.29 |
| Mutation burden, % | 1.05 | <.001 | 1.03-1.07 |
| Model 3 (including JAK2-mutated and MPL-mutated patients exclusively) | |||
| Age at diagnosis (y) | 1.01 | .227 | 0.99-1.04 |
| MPL exon 10 mutation vs JAK2 (V617F) | 2.67 | .066 | 0.94-7.57 |
| Mutation burden, >50% vs ≤50% | 15.45 | <.001 | 3.89-61.38 |
| Risk factors for the presence of fibrosis (covariates) . | Odds ratio . | P . | 95% CI . |
|---|---|---|---|
| Model 1 (including JAK2-mutated, MPL-mutated, and JAK2/MPL-unmutated patients) | |||
| Age at diagnosis (y) | 1.01 | .225 | 0.99-1.03 |
| MPL exon 10 mutation vs JAK2 (V617F) | 3.22 | .017 | 1.24-8.40 |
| MPL exon 10 mutation vs JAK2/MPL-unmutated patients | 1.64 | .323 | 0.62-4.37 |
| Model 2 (including JAK2-mutated and MPL-mutated patients exclusively) | |||
| Age at diagnosis (y) | 1.01 | .396 | 0.99-1.04 |
| MPL exon 10 mutation vs JAK2 (V617F) | 2.42 | .116 | 0.80-7.29 |
| Mutation burden, % | 1.05 | <.001 | 1.03-1.07 |
| Model 3 (including JAK2-mutated and MPL-mutated patients exclusively) | |||
| Age at diagnosis (y) | 1.01 | .227 | 0.99-1.04 |
| MPL exon 10 mutation vs JAK2 (V617F) | 2.67 | .066 | 0.94-7.57 |
| Mutation burden, >50% vs ≤50% | 15.45 | <.001 | 3.89-61.38 |